Navigation Links
Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
Date:11/15/2010

NEW YORK, Nov. 15, 2010 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the Lazard Capital Markets 7th Annual Healthcare Conference, being held at the St. Regis Hotel in New York City.  Mr. Bentsur's presentation is scheduled to take place on Wednesday, November 17, 2010, at 10:00 a.m.

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex(TM) (ferric citrate), an ora
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
2. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
3. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
4. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
5. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
8. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
10. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NY (PRWEB) July 26, 2014 ... Review, H2, 2014" provides data on the Ischemic ... report provides elemental information and data relating to ... Stroke. , View full global Ischemic Stroke Research ... includes an overview of the trial numbers and ...
(Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
(Date:7/25/2014)... 25, 2014 WABC Radio show out of ... with Lorry Young will be hosting California-based Vet-Stem, Inc.’s Founder ... cell therapy in pets. Dr. Harman first visited the ... cell therapy for pets suffering from osteoarthritis and other degenerative ... Medicine industry forward. , Young has invited Dr. Harman back ...
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
Breaking Biology Technology:Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... April 11, 2012  Ikaria, Inc., a critical care ... for critically ill patients, today announced that Joseph ... In this role, Dr. Stauffer will be responsible ... regulatory activities related to Ikaria,s commercialized product, INOMAX® ...
... Advanced Biofuels, LLC, the biobutanol technology leader, commented ... patent infringement. (Logo: http://photos.prnewswire.com/prnh/20120209/MM50763LOGO ... for commercial production of isobutanol.  This is especially ... our ,188, ,889 and related patents filed by ...
... Systems Corporation has recently signed a strategic alliance ... Psyche,s award winning Anatomic Pathology solution, will be ... Lab, Siemens laboratory information system. ... is built on a contemporary architecture that is ...
Cached Biology Technology:Ikaria® Appoints Chief Medical Officer 2Ikaria® Appoints Chief Medical Officer 3Butamax™ Responds to Gevo Patent Infringement Lawsuit 2Psyche Systems Corporation Signs Strategic Alliance with Siemens Healthcare to Provide Anatomic Pathology Solutions 2
(Date:7/28/2014)... at Harvard University today announced that its human ... formed private company to accelerate development of pharmaceutical, ... The announcement follows a worldwide license agreement between ... start-up Emulate Inc., relating to the use of ... "This is a big win towards achieving our ...
(Date:7/28/2014)... RENO Norwegian explorer Roald Amundsen became the first ... 1911. More than 100 years later, an international team ... Research Institute (DRI) have proven that air pollution from ... 16 ice cores collected from widely spaced locations around ... created the most accurate and precise reconstruction to date ...
(Date:7/27/2014)... the asteroid strike that wiped them out if it ... scientists say. , A fresh study using up-to-date fossil ... build a new narrative of the prehistoric creatures, demise, ... in the few million years before a 10km-wide asteroid ... upheaval. This included extensive volcanic activity, changing sea levels ...
Breaking Biology News(10 mins):Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Dinosaurs fell victim to perfect storm of events, study shows 2
... May 4 TORONTO Greater levels of a brain protein ... and clinical depression are so common after childbirth according to an ... . Using an advanced brain imaging method, ... levels of brain MAO-A in healthy women four to six days ...
... French . , Explaining and understanding life ... Biologist Dr. Frdric Guichard is no exception in fact, ... reproduction and communication of mussels. Guichard says marine life ... fishery management and marine preservation practices. "If I kill mussels ...
... Dietetic Association has published an updated position paper on ... and their value, discusses barriers to participation and encourages ... helping children get and stay healthy. ADA,s updated ... Journal of the American Dietetic Association , represents ...
Cached Biology News:The bivalve effect 2ADA releases updated position paper on nutrition assistance programs for children 2
...
The large Dodeca stainer shaking rack holds the staining trays in the large Dodeca stainer....
... in this set of Antibody Microarray ... for a total of over 2100 ... internal control. Antibodies belonging to many ... cell cycle progression, signal transduction and ...
... is the most advanced thermal cycler ever ... performance, the Dyad also boasts graphical programming ... navigation via touch pad or mouse. ... economically expanded to a four-bay system with ...
Biology Products: